Evidence for factor IX-independent roles for factor XIa in blood coagulation

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 12, 2013, Pages 2118-2127

  Matafonov, A ^a,b   Cheng, Q ^a   Geng, Y ^a   Verhamme, I M ^a   Umunakwe, O ^a   Tucker, E I ^c   Sun, M F ^a   Serebrov, V ^d   Gruber, A ^c   Gailani, D ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b NATIONAL RESEARCH TOMSK POLYTECHNIC UNIVERSITY   (Russian Federation)

^c Oregon Health and Science University Department of Biomedical Engineering   (United States)

^d SIBERIAN STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Factor IX; Factor V; Factor X; Factor XI; Factor XIa

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 9; FERRIC CHLORIDE; PROTEIN ANTIBODY; PROTHROMBIN; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING FACTOR DEFICIENCY; BLOOD CLOTTING TIME; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; HEMOSTASIS; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOGENICITY; THROMBOSIS; ANIMAL; C57BL MOUSE; FACTOR IX; FACTOR V; FACTOR X; FACTOR XI; FACTOR XIA; IMMUNOLOGY; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DEGRADATION;

FACTOR IX; FACTOR V; FACTOR X; FACTOR XI; FACTOR XIA;

ANIMALS; BLOOD COAGULATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FACTOR IX; FACTOR XIA; HUMANS; MICE; MICE, INBRED C57BL; PROTEOLYSIS;

EID: 84889652258     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12435     Document Type: Article

References (32)

1. Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964; 202: 498-9.
2. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-12.
3. Brummel-Ziedins K, Mann KG. Molecular basis of blood coagulation. In: Hoffman RH, Benz EJ, Silberstein LE, Heslop HE, Weitz JI, Anastasi J, eds. Hematology, Basic Principles and Practice, 6th edn. Philadelphia, PA: Saunders Elsevier, 2013:1821-41.
4. Gailani D, Renne T, Emsley J. Factor XI and the contact system. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarkis SE, Ballabio A, Scriver CR, Childs B, Sly WS, eds. The Online Metabolic and Molecular Basis of Inherited Disease. Philadelphia, PA: Lippincott, Williams, and Wilkins, 2010:1-80.
5. Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C. In vivo roles of factor XII. Blood 2012; 120: 4296-303.
6. Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost 2009; 7(Suppl. 1): 84-7.
7. Löwenberg EC, Meijers JC, Monia BP, Levi M. Coagulation factor XI as a novel target for antithrombotic treatment. J Thromb Haemost 2010; 8: 2349-57.
8. Müller F, Gailani D, Renné T. Factor XI and XII as antithrombotic targets. Curr Opin Hematol 2011; 18: 349-55.
9. Woodruff RS, Sullenger B, Becker RC. The many faces of the contact pathway and their role in thrombosis. J Thromb Thrombolysis 2011; 32: 9-20.
10. Whelihan MF, Orfeo T, Gissel MT, Mann KG. Coagulation procofactor activation by factor XIa. J Thromb Haemost 2010; 8: 1532-9.
11. Dharmawardana KR, Bock PE. Demonstration of exosite I-dependent interactions of thrombin with human factor V and factor Va involving the factor Va heavy chain: analysis by affinity chromatography employing a novel method for active-site-selective immobilization of serine proteinases. Biochemistry 1998; 37: 13143-52.
12. Geng Y, Verhamme IM, Messer A, Sun MF, Smith SB, Bajaj SP, Gailani D. A sequential mechanism for exosite-mediated factor IX activation by factor XIa. J Biol Chem 2012; 287: 38200-9.
13. Feuerstein GZ, Patel A, Toomey JR, Bugelski P, Nichols AJ, Church WR, Valocik R, Koster P, Baker A, Blackburn MN. Anti-thrombotic efficacy of a novel murine anti-human factor IX antibody in rats. Arterioscler Thromb Vasc Biol 1999; 19: 2554-62.
14. Kravtsov DV, Matafonov A, Tucker EI, Sun MF, Walsh PN, Gruber A, Gailani D. Factor XI contributes to thrombin generation in the absence of factor XII. Blood 2009; 114: 452-8.
15. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997; 90: 962-6.
16. Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, Sun MF, White-Adams TC, Smith SA, Hanson SR, McCarty OJ, Renné T, Gruber A, Gailani D. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010; 116: 3981-9.
17. Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu M-Y, Smith PL, Seiffert DA, Schumacher WA, Ogletree ML, Gailani D. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005; 3: 695-702.
18. Krem M, Rose T, Di Cera E. Sequence determinants of function and evolution in serine proteases. Trends Cardiovasc Med 2000; 10: 171-6.
19. Krishnaswamy S. Exosite-driven substrate specificity and function in coagulation. J Thromb Haemost 2005; 3: 54-67.
20. Bock PE, Panizzi P, Verhamme IM. Exosites in the substrate specificity of blood coagulation reactions. J Thromb Haemost 2007; 5(Suppl. 1): 81-94.
21. Ponczek MB, Gailani D, Doolittle RF. Evolution of the contact phase of vertebrate blood coagulation. J Thromb Haemost 2008; 6: 1876-83.
22. Geng Y, Verhamme IM, Sun MF, Paul Bajaj S, Emsley J, Gailani D. Analysis of the factor XI variant Arg184Gly suggests a structural basis for factor IX binding to factor XIa. J Thromb Haemost 2013; 11: 1374-84.
23. Maas C, Meijers JC, Marquart JA, Bakhtiari K, Weeterings C, de Groot PG, Urbanus RT. Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma. Proc Natl Acad Sci USA 2010; 107: 9083-7.
24. Puy C, Tucker EI, Wong ZC, Gailani D, Smith SA, Choi SH, Morrissey JH, Gruber A, McCarty OJT. Factor XII promotes blood coagulation independent of factor XI in the presence of long chain polyphosphate. J Thromb Haemost 2013; 11: 1341-52.
25. Jiang Y, Doolittle RF. The evolution of vertebrate blood coagulation as viewed from a comparison of puffer fish and sea squirt genomes. Proc Natl Acad Sci USA 2003; 100: 7527-32.
26. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 2006; 108: 4045-51.
27. Suri MF, Yamagishi K, Aleksic N, Hannan PJ, Folsom AR. Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Cerebrovasc Dis 2010; 29: 497-502.
28. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342: 696-701.
29. Mannucci PM, Bauer KA, Santagostino E, Faioni E, Barzegar S, Coppola R, Rosenberg RD. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood 1994; 84: 1314-19.
30. Richards EM, Makris MM, Cooper P, Preston FE. In vivo coagulation activation following infusion of highly purified factor XI concentrate. Br J Haematol 1997; 96: 293-7.
31. Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000; 65: 30-4.
32. Etscheid M, Breitner-Ruddock S, Gross S, Hunfeld A, Seitz R, Dodt J. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products. Vox Sang 2012; 102: 40-6.